Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study

Table 1

Baseline characteristics of the LA 3-month depot and 1-month depot groups.

Variables	LA-3 mon (n = 31)	LA-1 mon (n = 47)	P value
Age (yr)	8.89 ± 0.80	9.19 ± 1.05	0.312
FPG (mmol/L)	5.40 ± 0.42	5.35 ± 0.49	0.779
Serum TC (mmol/L)	4.22 ± 0.42	4.57 ± 0.91	0.370
Serum TG (mmol/L)	1.10 ± 0.27	1.40 ± 0.72	0.302
Serum LDL-C (mmol/L)	2.38 ± 0.15	2.57 ± 0.61	0.440
THt (cm)	159.43 ± 3.78	160.08 ± 3.29	0.450
Height (cm)	139.32 ± 5.56	140.55 ± 6.62	0.401
Weight (kg)	34.68 ± 5.14	37.05 ± 9.34	0.205
BMI (kg/m^2)	17.85 ± 2.24	18.54 ± 3.49	0.337
Tanner stage
2	22/31 (70.97%)	30/46 (65.22%)
3	9/31 (29.03%)	16/46 (34.78%)
Bone age (yr)	10.96 ± 0.59	10.84 ± 0.94	0.527
Serum basal LH (IU/L)	2.11 ± 1.83	2.82 ± 2.31	0.172
Serum basal FSH (IU/L)	4.11 ± 1.31	4.65 ± 1.68	0.155
Serum peak LH (IU/L)	27.91 ± 19.16	27.29 ± 17.94	0.901
Serum peak FSH (IU/L)	13.17 ± 4.89	14.35 ± 8.53	0.524
Serum peak LH/FSH	6.75 ± 4.15	5.64 ± 4.59	0.545
Serum E2 (pg/ml)	24.44 ± 11.84	29.39 ± 15.35	0.205
U-MD (cm)	2.48 ± 0.48	2.69 ± 0.58	0.141
RO-V (ml)	2.50 ± 0.93	3.07 ± 1.45	0.101
LO-V (ml)	2.44 ± 0.95	2.98 ± 1.28	0.106

Data are presented as mean ± standard deviation or number (%). Abbreviations: LA, Leuprorelin acetate; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; THt, target height; BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, estradiol; U-MD, maximum diameter of uterus; LO-V, volume of left ovary; RO-V, volume of right ovary.